G1 Therapeutics’ trilaciclib combiation improves breast cancer overall survival

G1 Therapeutics announced the presentation of mature Phase 2 clinical trial results describing the positive impact of trilaciclib in combination with a TROP2 ADC on overall survival and tolerability compared to SG alone. The poster is being presented at the 2024 ASCO meeting May 31 to June 4. The poster describes the mature results from a Phase 2 trial of trilaciclib in combination with SG in patients with metastatic triple negative breast cancer, or mTNBC. Patients receiving trilaciclib with the ADC experienced an approximately four-month improvement in median OS vs. that expected from the ADC alone based on historical data and had a 12-month survival of 60%. A 48% or approximately six-month improvement in median OS was observed in patients receiving trilaciclib in combination with SG compared to historical data from SG alone. Prolonged OS was observed in patients receiving trilaciclib with the ADC who had an initial breast cancer diagnosis of TNBC, prior use of checkpoint inhibitors, and no prior oral CDK4/6 inhibitor use. Trilaciclib reduced adverse events associated with this ADC, including diarrhea, neutropenia, anemia, and thrombocytopenia. These results support further evaluation of trilaciclib prior to SG or other ADCs and will help determine the design of future pivotal combination trials.